

Note

Reformatsky Reaction to Alkynyl N-tert-Butanesulfinyl Imines: Lewis Acid Controlled Stereodivergent Synthesis of #-Alkynyl #-Aminoacids

Luis Fernández-Sánchez, Jose A. Fernandez-Salas, M. Carmen Maestro, and Jose Luis Garcia Ruano

J. Org. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.joc.8b01918 • Publication Date (Web): 14 Sep 2018

Downloaded from <http://pubs.acs.org> on September 17, 2018

Just Accepted


“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

Reformatsky Reaction to Alkynyl *N*-*tert*-Butanesulfinyl Imines: Lewis Acid Controlled Stereodivergent Synthesis of β -Alkynyl- β -Aminoacids

Luis Fernández-Sánchez,[‡] José A. Fernández-Salas,^{‡*} M. Carmen Maestro,^{‡*} Jose L. García Ruano[‡]

[‡] Departamento de Química Orgánica (módulo-1), Universidad Autónoma de Madrid, Cantoblanco, 28049-Madrid, Spain

KEYWORDS. Asymmetric synthesis, *N*-sulfinyl imines, β -aminoacids, Reformatsky reaction, stereodivergent




ABSTRACT: A highly diastereoselective Reformatsky reaction to *N*-*tert*-butanesulfinyl propargylaldimines and ketimines is presented. The reaction proceeded with excellent yields and diastereoselectivities provided by the sulfinyl group in the presence of Me_3Al . The use of TBSOTf as Lewis acid promoter switched the sense of the stereoinduction. Thus, this methodology allowed the stereodivergent asymmetric synthesis of β -alkynyl β -amino acid derivatives, from the same sulfinyl configuration by simply changing the Lewis acid promoter.

The development of efficient and practical strategies for the stereoselective construction of privileged structures is an ongoing objective and still holds a preferred position in organic chemistry research.¹ β -Amino acids constitute a fundamental class of building-blocks for the synthesis of significant molecules with interesting pharmacological applications, showing hypoglycemic and antiketogenic properties as well as antibacterial and antifungal activities.² Besides their intrinsic relevance, β -amino acids are precursors for β -lactams, which are important building blocks present in a large number of antibiotics.³ On the other hand, the corresponding β -peptides display high tendency towards the formation of stable secondary structures of notable biological transcendence.⁴ Moreover, β -amino acids have been widely used in modern organic chemistry as chiral templates for asymmetric synthesis.^{2a} Therefore, several groups have focused their attention on the development of efficient methods for the asymmetric synthesis of β -amino acids.^{2a,5} Addition to imines,⁵ including *N*-sulfinyl imines,⁶ of ester enolates or silyl ketene acetals^{4b,4i,4k,5f} and Reformatsky-type reagents⁷ have been the approaches of choice to face this challenge. Although significant efforts have been devoted to synthesis of β -amino acids, a number of challenges in connection with its substrate generality still persist, being the synthesis of challenging γ,δ -alkynyl- β -amino acid deriva-


tives one of them. Propargyl β -amino acids are a special class of non-proteinogenic amino acids. In addition to potentially changing biological properties, these amino acids are key intermediates for interesting compounds with pharmacological activity, such as Xemilofiban, which has proven to be a platelet aggregation inhibitor that can prevent ischemia, heart attacks and other major adverse cardiac events.⁸ In this regard, asymmetric synthesis of propargylamines have been well established,⁹ featuring the alkylation of imines as the preferred approach. Despite remarkable progress, the enolizable moiety makes the synthesis of related γ,δ -alkynyl- β -aminoacids¹⁰ inaccessible following this strategy. To circumvent this limitation, the use of alkynyl imines or their precursors¹¹ as substrates in Mannich-type stereoselective reactions has emerged in the last decades.¹² Snapper and Hoveyda described an efficient silver-catalyzed asymmetric Mannich reaction with chiral ligands of silyl ketene acetal, to *N*-*ortho*-methoxyphenyl alkynyl imine.^{12a} However, the *ortho*-methoxyphenyl directing group is difficult to remove, requiring an oxidative procedure incompatible with many functional groups. The diastereoselective synthesis of β -alkynyl β -amino acids has also been addressed using a chiral auxiliary in either the imine ((*S*)-phenylglycinol)^{12c} or the nucleophile (chiral phenol derivative).^{12d} Both methods only disclosed the reactivity of one

α,β -unsaturated imine and a multistep oxidative cleavage protocol for the amino acid deliverance is required. Recently, Maruoka and coworkers have followed a similar approach pursuing the synthesis of very challenging chiral α -tertiary amines by using alkynyl sulfinyl ketimines as platforms, though β -amino acids synthesis is not compatible with this methodology (A, Scheme 1).¹³ Taking all these precedents into consideration, the development of an efficient and general method for the asymmetric synthesis of β -alkynyl β -amino acid derivatives would be highly desirable. The great progress in the field of asymmetric synthesis over the past decades has allowed high control over the selectivity of a given reaction. However, access to the opposite diastereoisomer is not usually possible by using the same set of starting materials under similar reaction conditions. Thus, development of new methodologies that allow access to both stereoisomers by using the same configuration of the starting materials are highly desirable.^{5f,14} Herein, we describe a Reformatsky reaction to readily accessible *N*-sulfinyl alkynyl imines as chiral templates. Facile sulfinyl cleavage would lead to the synthesis of enantiopure β -alkynyl β -amino acid derivatives. This straightforward approach gives access to both stereoisomers of the desired γ,δ -alkynyl β -amino acids using the same configuration at the sulfur atom of the sulfinyl group. This stereodivergent approach relies on the use of different Lewis acids (B, Scheme 1), which efficiently switches the reactivity of the imine.

A. Maruoka's work: Asymmetric synthesis of α -tertiary amines:



B. This work: General and stereodivergent synthesis of β -alkynyl- β -amino acids:



Scheme 1. Previous works (A), present work (B).

We began our studies investigating the Reformatsky reaction of the α -bromo ester derivative **2a** and the alkynyl *N*-sulfinyl imine bearing a phenyl ring **1a** as model substrate (Table 1). After optimizing the amount of Reformatsky reagent (**2a**) and the temperature (entries 1-6), the reaction showed a good efficiency when carried out at -10 °C in presence of 4 equivalents of the α -bromo ester (entry 6). At -40 °C the reaction did not take place and the starting imine was recovered (entry 7). Gratifyingly, in the presence of AlMe_3 at -78 °C,¹⁵ the desired γ,δ -alkynyl- β -amino ester derivative **3a** was obtained with complete diastereoselectivity (>98:2) in 88% isolated yield (entry 9).

Table 1. Reformatsky reaction with alkynyl sulfinyl imines: Optimization.^a

Ent	L. Acids (eq.)	2a (eq.)	T (°C)	t (h)	Conv. ^{b,c} (%)	d.r. ^b (3a:3a')
1	-	2.5	rt	1.25	100 (75)	87:13
2 ^d	-	2	0	15	-	-
3	-	2.5	0	4	90	-
4	-	3.5	0	20	100 (72)	90:10
5	-	3.5	-10	5	20	-
6	-	4	-10	5	100 (84)	91:9
7	-	4	-40	18	-	-
8	$\text{Cu}(\text{OTf})_2$ (1.1)	4	rt	22	-	-
9	AlMe_3 (1.1)	4	-78	3	100 (88)	>98:2
10	$\text{BF}_3 \cdot \text{OEt}_2$ (2.1)	4	rt	22	100 (80)	86:14
11	TMSOTf (2.1)	4	-78	6	65 (62)	14:86
12	TBSOTf (2.1)	4	-78	6	100 (86)	7:93


^a All reactions were carried out with **1a** (0.1 mmol) and Zn (0.4 mmol) in 0.25 mL of THF. ^b Determined by ¹H-NMR. ^c Isolated yield of the major diastereoisomer in brackets. ^d Reaction carried out with 2 equiv. of Zn.

With the aim of developing a new stereodivergent procedure, which would allow us to synthesize both enantiomers of the corresponding alkynyl β -amino acid derivative starting from the same configuration at the sulfinyl group, we used a highly oxophilic Lewis acid which could potentially modify the transition state through which the reaction takes place. Consequently, when the reaction was performed in the presence of $\text{BF}_3 \cdot \text{OEt}_2$, compound with the *S* configuration (**3a**) was still obtained as major diastereoisomer (entry 10). TMSOTf reverses the selectivity of the reaction, leading to *R*-configured isomer with a reasonably high stereocontrol (entry 11). To our delight, when a more sterically hindered silyl derivative was used,

the diastereoselectivity was improved up to 93:7, since the facial discrimination increased as well (entry 12).

After optimizing the reaction conditions, we studied the scope of the reaction regarding the synthesis of the *S* isomer. The results were summarized in Scheme 1. Firstly, different substitution in the aryl unit was considered. Arenes bearing an electron-rich (OMe) and an electron-deficient group (CO₂Me) as well as a bromo group in both *ortho* and *para* position were well tolerated and the desired products were obtained with complete diastereoselectivity and from good to excellent yields (**3b-3e**). Aliphatic alkynyl imine **1f** led to the β -amino ester product in high yield and only one diastereomer was observed (**3f**). Similarly, imine **1g**, bearing a TMS-substituted alkyne, underwent efficient Reformatsky reaction to give versatile product **3g**.

Table 2. Highly diastereoselective Reformatsky reaction to alkynyl *N*-sulfinyl imines: AlMe₃.^a




^a All reactions were carried out with **1** (0.1 mmol), **2a** (0.4 mmol), Zn (0.4 mmol) and AlMe₃ (0.11 mmol) in 0.25 mL of THF. The diastereomeric ratio was determined by ¹H NMR. Isolated yields.

In addition to sulfinyl aldimines, the corresponding less reactive and challenging ketimines proved to be suitable substrates in the Me₃Al-promoted Reformatsky reaction. Thus, differently substituted aryl and alkyl terminus acetylene ketimines led to the desired β -amino ester with a α -tertiary amine moiety with complete diastereoselectivity (**3h-3k**). It should be noted, that chiral α -tertiary amines are fundamental and recurrent motifs in naturally occurring and synthetic bioactive compounds and their synthesis still stands as an important challenge in organic chemistry.^{13a} To the best of our knowledge, the synthesis

of such β -alkynyl β -tertiary amino acid derivatives has never been described. The absolute configuration of the asymmetric centers of **3g** were unequivocally assigned as (*R*, *S*) by X-ray crystallographic analysis.¹⁶

We then studied the Reformatsky reaction to alkynyl *N*-sulfinyl imines mediated by TBSOTf in order to evaluate the scope of reaction (Table 3). Regarding the aldimines, these new reaction conditions tolerated electron-rich (OMe) and electron-deficient groups (CO₂Me) as well as a bromo substituent in both *ortho* and *para* position of the phenyl group, leading to the desired β -amino ester products in good yields and diastereoselectivities (**3a'-e'**). Imines bearing alkyl and TMS substituted alkynes underwent efficient Reformatsky reaction, to give adducts **3f'** and **3g'** in good yields and very good diastereoselectivities. No reaction was observed with methyl ketimine **1h**.


Table 3. Highly diastereoselective Reformatsky reaction to alkynyl *N*-sulfinyl imines: TBSOTf.^a



^a All reactions were carried out with **1** (0.1 mmol), **2a** (0.4 mmol), Zn (0.4 mmol) and TBSOTf (0.21 mmol) in 0.25 mL of THF. The diastereomeric ratio was determined by ¹H NMR. Isolated yields of the major diastereoisomer.


We propose that the Reformatsky reaction proceeded via a chair-like transition state¹⁷ where both the bulky *tert*-butyl ester group and the substituent in the sulfinyl imine could occupy equatorial positions. The reaction with aldimines (*E* isomer) and ketimines (*Z* isomer) takes place through a common transition state, although the *E/Z* isomeric distribution of the starting imine should be considered. Me₃Al would be simply acting as Lewis acid, enhancing the reactivity of the imine.¹⁸ In this context, Me₃Al could also be involve in differentiating the two Me₃Al imine isomers reaction rates, which are in rapid equilibrium.^{13a,17a,19} Highly oxophilic Lewis acid (R₃SiOTf) could potentially coordinate to the oxygen atom of the sulfinyl group, disengaging the six-membered chair-like

transition state. Thus, the reaction would take place under non-chelation control. The *tert*-butyl group of the sulfinyl group would direct the approach of the nucleophile to the less hindered re-face of the imine, leading to the opposite configuration (*R*) at the carbon atom that bears the amino group (Scheme 2).



Scheme 2. Proposed transition states for AlMe_3 - and R_3SiOTf -mediated Reformatsky reactions

As mentioned above, apart from the high stereoselection provided, the *tert*-butane sulfinyl group is an easily removable auxiliary (Scheme 3). Treatment of sulfinamides **3a** and **3f** with HCl in methanol allows the efficient deprotection to the amino ester (**4a** and **4f**) in high yields without erosion in the enantiomeric purity, whereas deprotection of the optically pure β -alkynyl β -amino acid (**5a** and **5f**) was efficiently accomplished in the presence of H_2O .



Scheme 3. Sulfinyl group cleavage. Synthesis of β -alkynyl β -amino esters and β -amino acids

In conclusion, we have described a highly diastereoselective Reformatsky reaction to enantiopure alkynyl *N*-sulfinylimines. The methodology tolerates a reasonably high range of aldimines and ketimines bearing differently substituted alkynyl groups. In addition, by simply changing the Lewis acid promoter, the reactivity switched, and allowed to prepare selectively both epimers from *N*-sulfinylimines with the same configuration at the sulfur atom. Finally, the sulfinyl group can be easily removed, leading to the desired enantiomerically pure β -alkynyl β -amino acids.

EXPERIMENTAL SECTION

General considerations: All solvents were dried using activated 4Å molecular sieves and stored under nitrogen. 4Å molecular sieves, 1.6–2.5 mm of particle size, were activated by microwave (700W) (3 x 60 sec) and subsequent cycles of

vacuum/nitrogen. For thin layer chromatography (TLC) silica gel plates with fluorescence indicator 254 nm were used and compounds were visualized by irradiation with UV light and/or by treatment with a solution of potassium permanganate in water followed by heating. Flash column chromatography was performed using silica gel (230–400 mesh) and compressed air. Hexane, ethyl acetate, dichloromethane and diethyl ether for flash chromatography were acquired from commercial sources and were used without previous purification. Optical rotation was recorded in cells with 10 cm path length; the specific solvents and concentrations (in g/100 mL) are indicated. NMR spectra were acquired on a Bruker Avance 300 MHz spectrometer, running at 300, 75 and 282 MHz for ^1H , ^{13}C and ^{19}F respectively. Chemical shifts (δ) are reported in ppm relative to residual solvent signals (CDCl_3 , 7.26 ppm for ^1H NMR and 77.2 ppm for ^{13}C NMR respectively). ^{13}C NMR spectra were acquired on a broad band decoupled mode. The following abbreviations are used to describe peak patterns when appropriate: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), bs (broad singlet). Mass spectra (MS) were obtained by ESI ionization mode. High resolution mass spectra (HRMS) were performed by ESI ionization mode using a time of-flight (TOF) mass analyzer, as indicated for each compound. Zn, dust; <10 μ (2.5g). Zinc was previously activated by washing successively with HCl 5% (3 x 3ml), H_2O (3 x 3ml), acetone (3 x 3 ml) and anhydrous Et_2O (3 x 3 ml). Then, it was carefully dried under high vacuum.

N-sulfinyl imine synthesis.

General procedure A: Synthesis of *N*-sulfinyl aldimines (1a–g): To a solution of (*R*)-*tert*-butane sulfinamide (2.5 mmol) in anhydrous THF (6.5 mL) under argon atmosphere, a solution of the corresponding aldehyde (3 mmol) in anhydrous THF (1 mL) was added. Subsequently, $\text{Ti}(\text{OEt})_4$ (10 mmol) was added and the mixture was stirred at 40–45 $^\circ\text{C}$. After 16h, MeOH (2.5 mL) and a solution of saturated NaHCO_3 were added until formation of a yellow precipitate was observed. The crude of reaction was filtered over celite, dried with MgSO_4 and the solvent was evaporated under reduced pressure. The residue was purified by flash-column chromatography.

General procedure B. Synthesis of *N*-sulfinyl ketimines (1h–1k): To a solution of (*R*)-*tert*-butane sulfinamide (0.43 mmol) in anhydrous CH_2Cl_2 (5.6 mL) under argon atmosphere, a solution of the corresponding ketone (0.52 mmol) in anhydrous CH_2Cl_2 (1mL) was added. Subsequently, $\text{Ti}(\text{OEt})_4$ (1.7 mmol) was added and the mixture was heated at reflux. After 4 hours $\text{Ti}(\text{OEt})_4$ (1.72 mmol) was added. After 16h, MeOH (2.5 mL) and a solution of saturated NaHCO_3 were added until a formation of yellow precipitate was observed. The crude of reaction was filtered through celite, dried with MgSO_4 and the solvent was evaporated under reduced pressure. The residue was purified by flash-column chromatography.

(*R*,*E*)-2-Methyl-*N*-(3-phenylprop-2-ynylidene)propane-2-sulfinamide (**1a**)

Following the general procedure A, 3-phenylpropionaldehyde (3 mmol), gave **1a** (636 mg, 2.73 mmol, 91% yield). Eluent: *n*-hexane/AcOEt (8/1). $[\alpha]_D^{20}$ -242.0 (*c* 1.00, CHCl_3). ^1H NMR (CDCl_3): δ 8.03 (s, 1H), 7.60–7.57 (m, 2H), 7.46–7.35 (m, 3H), 1.26 (s, 9H). ^{13}C NMR (CDCl_3): δ 147.8, 132.6, 130.4, 128.6, 120.9, 100.1, 85.6, 58.4, 22.6. IR (NaCl): 2961, 2868, 2204, 1727, 1563, 1364, 1179, 1090 cm^{-1} . MS (ESI+) *m/z* (%): 489

(2M+Na)⁺ (61), 256 (M+Na)⁺ (87), 234 (M+H)⁺ (37), 178 (100), 115 (35). HRMS (ESI): *m/z* calcd for C₁₃H₁₆NOS [M+H]⁺: 234.0947, found: 234.0949.

(R_S,E)-N-[3-(4-Methoxyphenyl)prop-2-ynylidene]-2-methylpropane-2-sulfinamide (1b)

Following the general procedure A, 3-(4-methoxyphenyl)propionaldehyde (3 mmol), gave **1b** (731 mg, 2.76 mmol, 92% yield). Eluent: *n*-hexane/AcOEt (6/1). [α]_D²⁰ -168.5 (*c* 0.82, CHCl₃). ¹H NMR (CDCl₃): δ 8.01 (s, 1H), 7.54-7.51 (m, 2H), 6.90-6.87 (m, 2H), 3.83 (s, 3H), 1.25 (s, 9H). ¹³C NMR (CDCl₃): δ 161.4, 147.9, 134.6, 114.4, 113.2, 101.2, 85.3, 58.3, 55.4, 22.6. IR (NaCl): 2983, 2961, 2868, 2846, 2197, 1603, 1560, 1509, 1459, 1296, 1174, 1085, 1033 cm⁻¹. MS (ESI+) *m/z* (%): 549 (2M+Na)⁺ (60), 286 (M+Na)⁺ (8), 264 (M+1)⁺ (52), 208 (100), 180 (18), 139 (36). HRMS: *m/z* calcd for C₁₄H₁₈NO₂S [M+H]⁺: 264.1052, found: 264.1060.

(R_S,E)-Ethyl 4-[3-(tert-butylsulfinylimino)prop-1-ynyl]benzoate (1c)

Following the general procedure A, ethyl 4-(3-oxoprop-1-yn-1-yl)benzoate (3 mmol), gave **1c** (631 mg, 2.07 mmol, 69% yield). Eluent: *n*-hexane/AcOEt (6/1). [α]_D²⁰ -154.1 (*c* 0.85, CHCl₃). ¹H NMR (CDCl₃): δ 8.04 (s, 1H), 8.06-8.04 (m, 2H), 7.65-7.62 (m, 2H), 4.39 (c, *J* = 7.1 Hz, 2H), 1.39 (t, *J* = 7.1 Hz, 3H), 1.26 (s, 9H). ¹³C NMR (CDCl₃): δ 165.6, 147.5, 132.4, 132.4, 131.8, 129.6, 125.2, 98.5, 87.4, 61.4, 58.6, 22.6, 14.3. IR (NaCl): 2981, 2929, 2870, 2206, 1721, 1564, 1274, 1176, 1092 cm⁻¹. MS (ESI+) *m/z* (%): 633 (2M+Na)⁺ (55), 306 (M+1)⁺ (69), 250 (100), 187 (9). HRMS: *m/z* calcd for C₁₆H₂₀NO₃S [M+H]⁺: 306.1158, found: 306.1165.

(R_S,E)-N-[3-(4-Bromophenyl)prop-2-ynylidene]-2-methylpropane-2-sulfinamide (1d)

Following the general procedure A, ethyl 3-(4-bromophenyl)propionaldehyde (3 mmol), gave **1d** (758 mg, 2.43 mmol, 81% yield). Eluent: *n*-hexane/AcOEt (5/1). [α]_D²⁰ -130.6 (*c* 0.96, CHCl₃). ¹H NMR (CDCl₃): δ 8.00 (s, 1H), 7.54-7.50 (m, 2H), 7.45-7.41 (m, 2H), 1.25 (s, 9H). ¹³C NMR (CDCl₃): δ 147, 133.9, 132.0, 125.1, 119.8, 98.7, 86.4, 58.5, 22.6. IR (NaCl): 2961, 2926, 2868, 2205, 1562, 1486, 1179, 1090, 1011 cm⁻¹. MS (ESI+) *m/z* (%): 647 (2M+Na)⁺ (28), 314 (M+3)⁺ (66), 312 (M+1)⁺ (64), 258 (100), 256 (100). HRMS: *m/z* calcd for C₁₃H₁₄BrNOS [M+H]⁺: 312.0052, found: 312.0036.

(R_S,E)-N-[3-(2-Bromophenyl)prop-2-ynylidene]-2-methylpropane-2-sulfinamide (1e)

Following the general procedure A, 3-(2-bromophenyl)propionaldehyde (3 mmol), gave **1e** (727 mg, 2.34 mmol, 78% yield). Eluent: *n*-hexane/AcOEt (5/1); [α]_D²⁰ -171.1 (*c* 1.03, CHCl₃). ¹H NMR (CDCl₃): δ 8.08 (s, 1H), 7.64-7.58 (m, 2H), 7.34-7.24 (m, 2H), 1.26 (s, 9H). ¹³C NMR (CDCl₃): δ 147.6, 134.4, 132.8, 131.4, 127.2, 126.4, 123.3, 97.8, 89.1, 58.6, 22.6. IR (NaCl): 2961, 2926, 2867, 2206, 1561, 1470, 1179, 1090 cm⁻¹. MS (ESI+) *m/z* (%): 647 (2M+Na)⁺ (16), 312 (M+1)⁺ (53), 258 (100), 256 (100); HRMS: *m/z* calcd for C₁₃H₁₄BrNOS [M+H]⁺: 312.0052, found: 312.0045.

(R_S,E)-2-Methyl-N-(oct-2-ynylidene)propane-2-sulfinamide (1f)

Following the general procedure A, oct-2-ynal (3mmol), gave **1f** (361 mg, 1.59 mmol, 53% yield). Eluent: *n*-hexane/AcOEt

(6/1). The spectroscopic data are in accordance with the literature.²⁰

(R_S,E)-2-Methyl-N-[3-(trimethylsilyl)prop-2-ynylidene]propane-2-sulfinamide (1g)

Following the general procedure A, 3-(trimethylsilyl)propionaldehyde (3 mmol), gave **1g** (543 mg, 2.37 mmol, 79% yield). Eluent: *n*-hexane/AcOEt (from 7/1 to 3/1). [α]_D²⁰ -268.9 (*c* 0.85, CHCl₃). ¹H NMR (CDCl₃): δ 7.78 (s, 1H), 1.22 (s, 9H), 0.25 (s, 9H). ¹³C NMR (CDCl₃): δ 148.4, 108.4, 100.3, 59.0, 23.2, 0.0. IR (NaCl): 2962, 2928, 2902, 2869, 2202, 1563, 1365, 1250, 1098, 1070 cm⁻¹. MS (ESI+) *m/z* (%): 545 (68), 481 (2M⁺+Na) (16), 284 (26), 252 (M+Na)⁺ (22), 230 (M+1)⁺ (46), 174 (100), 156 (15). HRMS: *m/z* calcd for C₁₀H₂₀NOSSi [M+H]⁺: 230.1029, found: 230.1021.

(R_S,Z)-2-methyl-N-(4-phenylbut-3-yn-2-ylidene)propane-2-sulfinamide (1h)^{13a}

Following the general procedure B, 4-phenylbut-3-yn-2-one (0.43 mmol), gave **1h** (80 mg, 0.3225 mmol, 75% yield) as a mixture of isomers *Z:E* (93:7). Eluent: *n*-hexane/AcOEt (5/1). [α]_D²⁰ -208.3 (*c* 0.70, CHCl₃). ¹H NMR (CDCl₃): δ 7.57-7.54 (m, 2H), 7.46-7.35 (m, 3H), 2.46 (s, 3H), 1.27 (s, 9H); ¹³C NMR (CDCl₃): δ 162.1, 132.5, 130.5, 128.6, 120.7, 102.2, 84.2, 56.9, 29.4, 22.2. IR (NaCl): 2982, 2926, 2865, 2209, 2158, 1563, 1365, 1178, 1081 cm⁻¹. MS (ESI+) *m/z* (%): 517 (2M⁺+Na) (90), 270 (M+Na)⁺ (17), 248 (M+1)⁺ (23), 192 (100). HRMS: *m/z* calcd for C₁₄H₁₈NOS [M+H]⁺: 248.1103, found: 248.1108.

(R_S,Z)-N-[4-(2-Methoxyphenyl)but-3-yn-2-ylidene]-2-methylpropane-2-sulfinamide (1i)

Following the general procedure B, 4-(2-methoxyphenyl)but-3-yn-2-one (0.43 mmol), gave **1i** (103 mg, 0.37 mmol, 86% yield). Eluent: *n*-hexane/AcOEt (from 4/1 to 3/1). [α]_D²⁰ -212.9 (*c* 0.70, CHCl₃). ¹H NMR (CDCl₃): δ 7.49 (d, *J* = 7.5 Hz, 1H), 7.39 (t, *J* = 7.9 Hz, 1H), 6.96-6.88 (m, 2H), 3.88 (s, 3H), 2.46 (s, 3H), 1.26 (s, 9H). ¹³C NMR (CDCl₃): δ 162.4, 161.1, 134.6, 132.4, 120.6, 110.9, 109.8, 99.4, 88.3, 57.0, 55.8, 29.2, 22.2.; IR (NaCl): 2961, 2210, 2118, 1568, 1491, 1463, 1280, 1249, 1087cm⁻¹. MS (FAB+) *m/z* (%): 555 (2M+1)⁺ (18), 278 (M+1)⁺ (100), 222 (58), 57 (21). HRMS: *m/z* calcd for C₁₅H₂₀NO₂S [M+H]⁺: 278.1215, found: 278.1219.

(R_S,Z)-N-[4-(4-Bromophenyl)but-3-yn-2-ylidene]-2-methylpropane-2-sulfinamide (1j)

Following the general procedure B, 4-(2-methoxyphenyl)but-3-yn-2-one (0.43 mmol), gave **1j** (129 mg, 0.4 mmol, 92% yield) as a mixture of isomers *Z:E* (92:8). Eluent: *n*-hexane/AcOEt (from 8/1 to 2/1). [α]_D²⁰ -311.9 (*c* 0.61, CHCl₃). ¹H NMR (CDCl₃): δ 7.53-7.40 (AA'BB' system, 4H), 2.45 (s, 3H), 1.26 (s, 9H). ¹³C NMR (CDCl₃): δ 161.4, 133.91, 132.0, 125.3, 119.5, 100.9, 85.2, 57.1, 29.3, 22.2. IR (NaCl): 2968, 2924, 2865, 2211, 1558, 1471, 1081 cm⁻¹. MS (FAB+) *m/z* (%): 651 (2M+1)⁺ (9), 326 (M+1)⁺ (96), 272 (56), 270 (59), 57 (86). HRMS: *m/z* calcd for C₁₄H₁₇NOSBr [M+H]⁺: 326.0214, found: 326.0218.

(R_S,Z)-N-(Hex-3-yn-2-ylidene)-2-methylpropane-2-sulfinamide (1k)

Following the general procedure B, hex-3-yn-2-one (0.43 mmol), gave **1k** (63 mg, 0.32 mmol, 73% yield). Eluent: *n*-hexane/AcOEt (4/1). [α]_D²⁰ -242.6 (*c* 0.67, CHCl₃). ¹H NMR (CDCl₃): δ 2.42 (q, *J* = 7.4 Hz, 2H), 2.31 (s, 3H), 1.22-1.17

(m, 3H), 1.20 (s, 9H). ^{13}C NMR (CDCl_3): δ 163.4, 106.9, 76.3, 56.5, 29.5, 22.0, 13.3, 12.8. IR (NaCl): 2980, 2215, 1578, 1364, 1252, 1088 cm^{-1} . MS (FAB+) m/z (%): 399 ($2\text{M}+1$) $^+$ (10), 200 ($\text{M}+1$) $^+$ (100), 144 (53), 57 (34). HRMS: m/z calcd for $\text{C}_{10}\text{H}_{18}\text{NOS}$ [$\text{M}+\text{H}$] $^+$: 200.1109, found: 200.1107.

Diastereoselective Reformatsky reaction to imines.

General procedure C. Table 2. *AlMe*₃: To a solution of the corresponding imine (0.086 mmol) in anhydrous THF (0.2 mL) under argon atmosphere at -78 °C, AlMe_3 (0.0946 mmol) was added, and the mixture stirred for 5 min. Then, organozinc reagent²¹ was dropwise added at -78 °C. After the time indicated at the table 2, NH_4Cl (sat. solution, 1.5 mL) was added. The organic phase was separated, and the aqueous layer was extracted with Et_2O (2 x 10mL) and CH_2Cl_2 (10 mL), dried over MgSO_4 , filtered and the solvent evaporated under reduced pressure. The residue was purified by flash-column chromatography.

General procedure D. Table 3. *TBSOTf*: To a solution of the corresponding imine (0.086 mmol) in anhydrous THF (0.2 mL) under argon atmosphere at -78 °C, *TBSOTf* (0.181 mmol) was added. The mixture was stirred 5 min. To the resulting mixture organozinc reagent⁴ was added dropwise at -78 °C. After the time indicated in the table 3, NH_4Cl (sat. solution, 1.5 mL) was added. The organic phase was separated and the aqueous layer was extracted with Et_2O (2 x 10mL) and CH_2Cl_2 (10 mL), dried over MgSO_4 , filtered and the solvent was evaporated under reduced pressure. The residue was purified by flash-column chromatography.

tert-Butyl (S)-3-[(*R*_S)-1,1-dimethylethylsulfonamido]-5-phenylpent-4-ynoate (**3a**)

Following the general procedure C, imine **1a** (0.43 mmol) after 3h, gave **3a** as major diastereoisomer (132 mg, 0.38 mmol, 88% yield). Eluent: *n*-hexane/AcOEt, (2/1). $[\alpha]_{\text{D}}^{20}$ -59.4 (*c* 0.63, CHCl_3). ^1H NMR (CDCl_3): δ 7.43-7.40 (m, 2H), 7.31-7.27 (2m, 3H), 4.70-4.64 (m, 1H), 4.41 (d, *J* = 6.7 Hz, 1H), 2.88 (dd, *J* = 15.9, 5.2 Hz, 1H), 2.78 (dd, *J* = 15.9, 7.0 Hz, 1H), 1.48 (s, 9H), 1.26 (s, 9H); ^{13}C NMR (CDCl_3): δ 169.7, 131.7, 128.5, 128.3, 122.5, 87.1, 85.1, 81.8, 56.0, 45.4, 42.8, 28.1, 22.6. IR (NaCl): 2979, 2928, 2203, 1731, 1367, 1154, 1069 cm^{-1} ; MS (ESI+): m/z (%): 721 ($2\text{M}+\text{Na}$) $^+$ (100), 699 ($2\text{M}+1$) $^+$ (48), 350 ($\text{M}+1$) $^+$ (16), 294 (40). HRMS: m/z calcd for $\text{C}_{19}\text{H}_{28}\text{NO}_3\text{S}$ [$\text{M}+\text{H}$] $^+$: 350.1784; found: 350.1787.

tert-Butyl (S)-3-{[(*R*_S)-*tert*-butylsulfanyl]amino}-5-(4-methoxyphenyl)pent-4-ynoate (**3b**)

Following the general procedure C, imine **1b** (0.43 mmol) after 3h, gave **3a** as major diastereoisomer (137 mg, 0.36 mmol, 84% yield). Eluent: *n*-hexane/AcOEt, (2/1). 97 % *e.d.* (Chiralcel OD, 1.0 mL/min, hexane/*i*PrOH (95:5), $\lambda=254\text{nm}$, $t_{\text{RR}} = 12.0$ min, $t_{\text{RS}} = 19.6$ min, $[\alpha]_{\text{D}}^{20}$ -41.9 (*c* 1.08, CHCl_3). ^1H NMR (CDCl_3): δ 7.39-7.32 (m, 2H), 6.84-6.79 (m, 2H), 4.67-4.61 (m, 1H), 4.38 (d, *J* = 6.7 Hz, 1H), 3.80 (s, 3H), 2.87 (dd, *J* = 15.8, 5.2 Hz, 1H), 2.77 (dd, *J* = 15.8, 7.0 Hz, 1H), 1.47 (s, 9H), 1.25 (s, 9H). ^{13}C NMR (CDCl_3): δ 169.8, 159.8, 133.2, 114.6, 113.9, 85.7, 85.1, 81.7, 56.0, 55.3, 45.5, 43.0, 28.1, 22.6. IR (NaCl): 2980, 2924, 2198, 1731, 1366, 1249, 1153 cm^{-1} . MS (ESI+): m/z (%): 781 ($2\text{M}+\text{Na}$) $^+$ (26), 759 ($2\text{M}+1$) $^+$ (100), 380 ($\text{M}+1$) $^+$ (4). HRMS: m/z calcd for $\text{C}_{20}\text{H}_{30}\text{NO}_4\text{S}$ [$\text{M}+\text{H}$] $^+$: 380.1890, found: 380.1890.

Ethyl 4-((*S*)-5-(*tert*-butoxy)-3-[(*R*_S)-1,1-dimethylethylsulfonamido]-5-oxopent-1-yn-1-yl)benzoate (**3c**)

Following the general procedure C, imine **1c** (0.43 mmol) after 16h, gave **3c** as major diastereoisomer (156 mg, 0.37 mmol, 86% yield). Eluent: *n*-hexane/AcOEt, (3/1 to 2/1). $[\alpha]_{\text{D}}^{20}$ -48.6 (*c* 1.48, in CHCl_3); ^1H NMR (CDCl_3): δ 8.00-7.88 (m, 2H), 7.51-7.39 (m, 2H), 4.70-4.64 (m, 1H), 4.42 (d, *J* = 6.8 Hz, 1H), 4.36 (c, *J* = 7.2 Hz, 2H), 2.89 (dd, *J* = 16.0, 5.1 Hz, 1H), 2.79 (dd, *J* = 15.9, 7.0 Hz, 1H), 1.47 (s, 9H), 1.38 (t, *J* = 7.2 Hz, 3H), 1.25 (s, 9H). ^{13}C NMR (CDCl_3): δ 169.6, 166.0, 131.6, 130.2, 129.4, 127.0, 90.1, 84.4, 81.9, 61.2, 56.1, 45.4, 42.6, 28.1, 22.6, 14.3. IR (NaCl): 2979, 2927, 2205, 1720, 1606, 1458, 1367, 1273, 1163 cm^{-1} . MS (ESI+): m/z (%): 865 ($2\text{M}+\text{Na}$) $^+$ (15), 843 ($2\text{M}+1$) $^+$ (100), 444 ($\text{M}+\text{Na}$) $^+$ (4), 422 ($\text{M}+1$) $^+$ (8), 366 (22). HRMS: m/z calcd for $\text{C}_{22}\text{H}_{32}\text{NO}_5\text{S}$ [$\text{M}+\text{H}$] $^+$: 422.1995, found: 422.1970.

tert-Butyl (S)-5-(4-bromophenyl)-3-[(*R*_S)-1,1-dimethylethylsulfonamido]pent-4-ynoate (**3d**)

Following the general procedure C, imine **1d** (0.43 mmol) after 2h, gave **3d** as major diastereoisomer (158 mg, 0.37 mmol, 86% yield). Eluent: *n*-hexane/AcOEt, (3/1 to 2/1). $[\alpha]_{\text{D}}^{20}$ -47.6 (*c* 0.70, in CHCl_3). ^1H NMR (CDCl_3): δ 7.37-7.34 (m, 2H), 7.21-7.18 (m, 2H), 4.67-4.60 (m, 1H), 4.39 (d, *J* = 6.7 Hz, 1H), 2.80 (dd, *J* = 15.9, 5.2 Hz, 1H), 2.71 (dd, *J* = 16.0, 7.0 Hz, 1H), 1.48 (s, 9H), 1.24 (s, 9H). ^{13}C NMR (CDCl_3): δ 169.6, 133.1, 131.5, 122.8, 121.4, 88.3, 84.1, 81.8, 56.0, 45.3, 42.6, 28.1, 22.6. IR (NaCl): 2978, 2923, 2208, 1729, 1486, 1367, 1153, 1070 cm^{-1} . MS (ESI+): m/z (%): 879 ($2\text{M}+\text{Na}$) $^+$ (27), 857 ($2\text{M}+1$) $^+$ (100), 430 ($\text{M}+3$) $^+$ (27), 428 ($\text{M}+1$) $^+$ (24). HRMS: m/z calcd for $\text{C}_{19}\text{H}_{26}\text{NO}_3\text{SBr}$ [$\text{M}+\text{H}$] $^+$: 428.0889, found: 428.0871.

tert-Butyl (S)-5-(2-bromophenyl)-3-[(*R*_S)-1,1-dimethylethylsulfonamido]pent-4-ynoate (**3e**)

Following the general procedure C, imine **1e** (0.43 mmol) after 10 h, gave **3e** as major diastereoisomer (180 mg, 0.42 mmol, 98% yield). Eluent: *n*-hexane/AcOEt, (3/1 to 2/1). $[\alpha]_{\text{D}}^{20}$ -56.9 (*c* 0.50, in CHCl_3); ^1H NMR (CDCl_3): δ 7.56-7.54 (m, 1H), 7.45-7.42 (m, 1H), 7.26-7.21 (m, 1H), 7.18-7.12 (m, 1H), 4.74-4.68 (m, 1H), 4.46 (d, *J* = 6.8 Hz, 1H), 2.86 (dd, *J* = 16.1, 5.1 Hz, 1H), 2.76 (dd, *J* = 16.1, 6.8 Hz, 1H), 1.47 (s, 9H), 1.25 (s, 9H). ^{13}C NMR (CDCl_3): δ 169.6, 133.5, 132.4, 129.6, 127.0, 125.6, 124.6, 91.8, 83.6, 81.8, 56.1, 45.5, 42.6, 28.1, 22.6. IR (NaCl): 2979, 2928, 2870, 2206, 1729, 1471, 1367, 1154, 1062 cm^{-1} . MS (ESI+): m/z (%): 879 ($2\text{M}+\text{Na}$) $^+$ (40), 857 ($2\text{M}+1$) $^+$ (100), 428 ($\text{M}+1$) $^+$ (27). HRMS: m/z calcd for $\text{C}_{19}\text{H}_{26}\text{NO}_3\text{SBr}$ [$\text{M}+\text{H}$] $^+$: 428.0889, found: 428.0867.

tert-Butyl (S)-3-[(*R*_S)-1,1-dimethylethylsulfonamido]dec-4-ynoate (**3f**)

Following the general procedure C, imine **1f** (0.43 mmol) after 5 h, gave **3f** as major diastereoisomer (136 mg, 0.40 mmol, 92% yield). Eluent: *n*-hexane/AcOEt, (3/1 to 1/1). $[\alpha]_{\text{D}}^{20}$ -57.6 (*c* 1.76, in CHCl_3). ^1H NMR (CDCl_3): δ 4.43-4.37 (m, 1H), 4.25 (d, *J* = 6.2 Hz, 1H), 2.74 (dd, *J* = 15.9, 5.2 Hz, 1H), 2.65 (dd, *J* = 15.9, 7.0 Hz, 1H), 2.16 (dt, *J* = 2.0, 7.0 Hz, 2H), 1.45 (s, 9H), 1.40-1.27 (m, 5H), 1.22 (s, 9H), 0.88 (t, *J* = 6.9 Hz, 3H). ^{13}C NMR (CDCl_3): δ 169.9, 86.0, 81.5, 78.0, 55.8, 44.9, 43.2, 31.0, 28.2, 28.1, 22.6, 22.2, 18.6, 14.0. IR (NaCl): 2959, 2932, 2862, 2204, 1732, 1367, 1156, 1061 cm^{-1} . MS (ESI+): m/z (%): 709 ($2\text{M}+\text{Na}$) $^+$ (100), 687 ($2\text{M}+1$) $^+$ (34), 344 ($\text{M}+1$) $^+$ (29), 288 (76), 214 (13). HRMS: m/z calcd for $\text{C}_{18}\text{H}_{34}\text{NO}_3\text{S}$ [$\text{M}+\text{H}$] $^+$: 344.2253; found: 344.2259.

tert-Butyl (S)-3-[(*R*_S)-1,1-dimethylethylsulfonamido]-5-(trimethylsilyl)pent-4-ynoate (**3g**)

Following the general procedure C, imine **1g** (0.43 mmol) after 16 h, gave **3g** as major diastereoisomer (138 mg, 0.4 mmol, 93% yield). Eluent: *n*-hexane/AcOEt, (2/1). $[\alpha]_D^{20}$ -56.9 (*c* 0.70, in CHCl₃). ¹H NMR (CDCl₃): δ 4.43-4.37 (m, 1H), 4.31 (d, *J* = 7.4 Hz, 1H), 2.64 (dd, *J* = 15.9, 5.2 Hz, 1H), 2.53 (dd, *J* = 15.9, 6.6 Hz, 1H), 1.45 (s, 9H), 1.21 (s, 9H), 0.13 (s, 9H). ¹³C NMR (CDCl₃): δ 169.9, 103.7, 89.9, 81.9, 56.2, 45.8, 43.0, 28.3, 22.8, 0.0. IR (NaCl): 2955, 2929, 2207, 2867, 1737, 1315, 1153, 1055 cm⁻¹. MS (ESI+): *m/z* (%): 713 (2M+Na)⁺ (100), 691 (2M+1)⁺ (30), 346 (M⁺+1) (34), 290 (90). HRMS: *m/z* calcd for C₁₆H₃₂NO₃SSi [M+H]⁺: 346.1866; found: 346.1882.

tert-Butyl (*R*)-3-[(*R*_S)-1,1-dimethylethylsulfonamido]-3-methyl-5-phenylpent-4-ynoate (**3h**)

Following the general procedure C, imine **1h** (0.43 mmol) after 16 h, gave **3h** as major diastereoisomer (116 mg, 0.32 mmol, 74% yield). Eluent: *n*-hexane/AcOEt, (4/1 to 2/1). $[\alpha]_D^{20}$ -87.9 (*c* 0.72, in CHCl₃). ¹H NMR (CDCl₃): δ 7.43-7.40 (m, 2H), 7.26-7.24 (m, 3H), 4.90 (s, 1H), 2.83 (d, *J* = 15.1 Hz, 1H), 2.59 (d, *J* = 15.1 Hz, 1H), 1.63 (s, 3H), 1.44 (s, 9H), 1.21 (s, 9H). ¹³C NMR (CDCl₃): δ 169.8, 131.8, 128.3, 128.2, 122.6, 90.4, 85.1, 81.9, 55.8, 51.6, 48.3, 29.3, 28.2, 22.6. IR (NaCl): 2980, 2926, 2210, 1720, 1369, 1159, 1070 cm⁻¹. MS (ESI+): *m/z* (%): 749 (2M+Na)⁺ (100), 727 (2M+1)⁺ (28), 364 (M+1)⁺ (51), 308 (66), 187 (74), 122 (45). HRMS: *m/z* calcd for C₂₀H₃₀NO₃S [M+H]⁺: 364.1940; found: 364.1954.

tert-Butyl (*R*)-3-[(*R*_S)-1,1-dimethylethylsulfonamido]-5-(2-methoxyphenyl)-3-methylpent-4-ynoate (**3i**)

Following the general procedure C, imine **1i** (0.43 mmol) after 16 h, gave **3i** as major diastereoisomer (159 mg, 0.4 mmol, 94% yield). Eluent: *n*-hexane/AcOEt, (2/1). $[\alpha]_D^{20}$ -90.1 (*c* 0.80, in CHCl₃). ¹H NMR (CDCl₃): δ 7.44-7.41 (m, 1H), 7.27-7.21 (m, 1H), 7.88-7.81 (m, 2H), 4.86 (s, 1H), 3.83 (s, 3H), 2.97 (d, *J* = 10.6, 1H), 2.69 (d, *J* = 10.6, 1H), 1.65 (s, 3H), 1.46 (s, 9H), 1.23 (s, 9H). ¹³C NMR (CDCl₃): δ 169.9, 160.1, 134.0, 129.7, 120.4, 112.0, 110.9, 94.2, 81.7, 55.8, 55.7, 52.0, 48.1, 29.3, 28.1, 22.6, 22.2. IR (NaCl): 2979, 2932, 2210, 17319, 1575, 1494, 1369, 1247, 1161 cm⁻¹. MS (ESI+): *m/z* (%): 416 (M+Na)⁺ (36), 394 (M+1)⁺ (72), 217 (100). HRMS: *m/z* calcd for C₂₁H₃₂NO₄S [M+H]⁺: 394.2046; found: 394.2064.

tert-butyl (*R*)-5-(4-bromophenyl)-3-[(*R*_S)-1,1-dimethylethylsulfonamido]-3-methylpent-4-ynoate (**3j**)

Following the general procedure C, imine **1j** (0.43 mmol) after 16 h, gave **3j** as major diastereoisomer (132 mg, 0.3 mmol, 70% yield). Eluent: *n*-hexane/AcOEt, (4/1). $[\alpha]_D^{20}$ -70.3 (*c* 0.52, in CHCl₃). ¹H NMR (CDCl₃): δ 7.42-7.39 (m, 2H), 7.31-7.26 (m, 2H), 4.94 (s, 1H), 2.85 (d, *J* = 15.0, 1H), 2.63 (d, *J* = 15.0, 1H), 1.63 (s, 3H), 1.46 (s, 9H), 1.23 (s, 9H). ¹³C NMR (CDCl₃): δ 169.7, 133.2, 131.4, 122.6, 121.6, 91.6, 84.0, 82.0, 55.9, 51.4, 48.2, 29.1, 28.1, 22.6. IR (NaCl): 3194, 2973, 2953, 1739, 1488, 1352, 1217, 1156, 1131, 1052 cm⁻¹. MS (ESI+): *m/z* (%): 442 (M+1)⁺ (22), 267 (32), 265 (31), 122 (54), 57 (100). HRMS: *m/z* calcd for C₂₀H₂₉NO₃SBr [M+H]⁺: 442.1052; found: 442.1038.

tert-Butyl (*R*)-3-[(*R*_S)-1,1-dimethylethylsulfonamido]-3-methylhept-4-ynoate (**3k**)

Following the general procedure C, imine **1k** (0.43 mmol) after 16 h, gave **3k** as major diastereoisomer (121 mg, 0.39 mmol, 89% yield). Eluent: *n*-hexane/AcOEt, (4/1). $[\alpha]_D^{20}$ -89.6 (*c* 0.51, in CHCl₃). ¹H NMR (CDCl₃): δ 4.79 (s, 1H), 2.75

(d, *J* = 15.1 Hz, 1H), 2.52 (d, *J* = 15.1 Hz, 1H), 2.18 (c, *J* = 7.5 Hz, 2H), 1.51 (s, 3H), 1.45 (s, 9H), 1.19 (s, 9H), 1.10 (t, *J* = 7.5 Hz, 3H). ¹³C NMR (CDCl₃): δ 170.0, 87.1, 81.6, 80.6, 55.6, 51.1, 48.6, 29.5, 28.1, 22.6, 13.7, 12.4. IR (NaCl): 2979, 1719, 1458, 1236, 1158, 1068 cm⁻¹. MS (ESI+): *m/z* (%): 631 (2M+1)⁺ (19), 316 (M+1)⁺ (100), 260 (94), 186 (35), 57 (63). HRMS: *m/z* calcd for C₁₆H₃₀NO₃S [M+H]⁺: 316.1946; found: 316.1945.

tert-Butyl (*R*)-3-[(*R*_S)-1,1-dimethylethylsulfonamido]-5-phenylpent-4-ynoate (**3a'**)

Following the general procedure D, imine **1a** (0.086 mmol) after 5 h, gave **3a'** as major diastereoisomer (26 mg, 0.074 mmol, 86% yield). Eluent: *n*-hexane/AcOEt, (3/1 to 2/1). $[\alpha]_D^{20}$ -26.7 (*c* 0.66, in CHCl₃). ¹H NMR (CDCl₃): δ 7.43-7.40 (m, 2H), 7.30-7.27 (m, 3H), 4.67-4.60 (m, 1H), 3.98 (d, *J* = 6.7 Hz, 1H), 2.84 (dd, *J* = 15.9, 7.8 Hz, 1H), 2.73 (dd, *J* = 15.9, 5.5 Hz, 1H), 1.46 (s, 9H), 1.23 (s, 9H). ¹³C NMR (CDCl₃): δ 169.5, 131.8, 128.5, 128.2, 122.4, 87.4, 85.3, 81.6, 56.3, 45.4, 43.2, 28.1, 22.6.

tert-Butyl (*R*)-3-[(*R*_S)-1,1-dimethylethylsulfonamido]-5-(4-methoxyphenyl)pent-4-ynoate (**3b'**)

Following the general procedure D, imine **1b** (23 mg, 0.06 mmol, 0.086 mmol) after 4 h, gave **3b'** as major diastereoisomer (69% yield). Eluent: *n*-hexane/AcOEt, (3/1). $[\alpha]_D^{20}$ -24.7 (*c* 1.05, in CHCl₃). ¹H NMR (CDCl₃): δ 7.35 (d, *J* = 8.7 Hz, 2H), 6.81 (d, *J* = 8.7 Hz, 2H), 4.66-4.59 (m, 1H), 3.92 (d, *J* = 6.6 Hz, 1H), 3.79 (s, 3H), 2.83 (dd, *J* = 15.9, 7.8 Hz, 1H), 2.71 (dd, *J* = 15.8, 5.5 Hz, 1H), 1.46 (s, 9H), 1.22 (s, 9H). ¹³C NMR (CDCl₃): δ 169.5, 159.8, 133.2, 114.6, 113.9, 86.0, 85.2, 81.5, 56.2, 55.3, 45.5, 43.4, 28.1, 22.6.

Ethyl 4-[(*R*)-5-(*tert*-butoxy)-3-[(*R*_S)-1,1-dimethylethylsulfonamido]-5-oxopent-1-yn-1-yl]benzoate (**3c'**)

Following the general procedure D, imine **1c** (31 mg, 0.073 mmol, 0.086 mmol) after 4 h, gave **3c'** as major diastereoisomer (84% yield). Eluent: *n*-hexane/AcOEt, (3/1 to 2/1). $[\alpha]_D^{20}$ -18.1 (*c* 1.20, in CHCl₃). ¹H NMR (CDCl₃): δ 7.91-7.82 (m, 2H), 7.42-7.34 (m, 2H), 4.67-4.61 (m, 1H), 4.37-4.24 (m, 2H), 3.93-3.85 (m, 1H), 2.85-2.64 (m, 2H), 1.46 (s, 9H), 1.38 (t, *J* = 6.9 Hz, 3H), 1.22 (s, 9H). ¹³C NMR (CDCl₃): δ 169.3, 166.0, 131.7, 130.2, 129.4, 127.0, 90.3, 84.5, 81.7, 61.1, 56.4, 45.4, 43.0, 28.1, 22.5, 14.3.

tert-Butyl (*R*)-5-(4-bromophenyl)-3-[(*R*_S)-1,1-dimethylethylsulfonamido]pent-4-ynoate (**3d'**)

Following the general procedure D, imine **1d** (0.086 mmol) after 5 h, gave **3d'** as major diastereoisomer (31 mg, 0.072 mmol, 83% yield). Eluent: *n*-hexane/AcOEt, (3/1 to 2/1). $[\alpha]_D^{20}$ -4.8 (*c* 0.54, in CHCl₃). ¹H NMR (CDCl₃): δ 7.35 (d, *J* = 8.4 Hz, 2H), 7.21 (d, *J* = 8.4 Hz, 2H), 4.57-4.51 (m, 1H), 3.90 (d, *J* = 7.2 Hz, 1H), 2.76 (dd, *J* = 15.9, 7.7 Hz, 1H), 2.65 (dd, *J* = 15.9, 5.5 Hz, 1H), 1.39 (s, 9H), 1.16 (s, 9H). ¹³C NMR (CDCl₃): δ 169.4, 133.2, 131.5, 122.8, 121.4, 88.6, 84.2, 81.6, 56.3, 45.4, 43.0, 28.1, 22.5.

tert-Butyl (*R*)-5-(2-bromophenyl)-3-[(*R*_S)-1,1-dimethylethylsulfonamido]pent-4-ynoate (**3e'**)

Following the general procedure D, imine **1e** (0.086 mmol) after 6 h, gave **3e'** as major diastereoisomer (29 mg, 0.068 mmol, 78% yield). Eluent: *n*-hexane/AcOEt, (3/1 to 2/1). $[\alpha]_D^{20}$ -8.8 (*c* 0.60, in CHCl₃). ¹H NMR (CDCl₃): 7.56-7.53 (m, 1H), 7.48-7.45 (m, 1H), 7.26-7.20 (m, 1H), 7.18-7.12 (m, 1H), 4.73-4.66 (m, 1H), 4.01 (d, *J* = 6.7 Hz, 1H), 2.89 (dd, *J* = 16.2, 7.9 Hz, 1H), 2.79 (dd, *J* = 16.2, 5.4 Hz, 1H), 1.47 (s,

9H), 1.23 (s, 9H). ^{13}C NMR (CDCl_3): δ 169.4, 133.7, 132.3, 129.6, 127.0, 125.6, 124.6, 92.1, 83.8, 81.6, 56.3, 45.3, 43.0, 28.1, 22.6.

tert-Butyl (*R*)-3-[(*R*_S)-1,1-dimethylethylsulfonamido]dec-4-ynoate (**3f**)

Following the general procedure D, imine **1f** (0.086 mmol) after 5 h, gave **3f** as major diastereoisomer (22 mg, 0.062 mmol, 72% yield). Eluent: *n*-hexane/AcOEt, (2/1). $[\alpha]_{\text{D}}^{20}$ -31.8 (*c* 0.45, in CHCl_3). ^1H NMR (CDCl_3): δ 4.41-4.35 (m, 1H), 3.79 (d, *J* = 6.3 Hz, 1H), 2.71 (dd, *J* = 15.8, 7.8 Hz, 1H), 2.58 (dd, *J* = 15.9, 5.5 Hz, 1H), 2.16 (dt, *J* = 2.0, 6.9 Hz, 2H), 1.44 (s, 9H), 1.38-1.27 (m, 6H), 1.19 (s, 9H), 0.88 (t, *J* = 6.9 Hz, 3H). ^{13}C NMR (CDCl_3): δ 169.7, 86.1, 81.3, 78.3, 56.0, 45.0, 43.6, 31.0, 28.2, 28.1, 22.5, 22.1, 18.7, 13.9.

tert-Butyl (*R*)-3-[(*R*_S)-1,1-dimethylethylsulfonamido]-5-(trimethylsilyl)pent-4-ynoate (**3g**)

Following the general procedure D, imine **1g** (0.086 mmol) after 5 h, gave **3g** as major diastereoisomer (23 mg, 0.067 mmol, 77% yield). Eluent: *n*-hexane/AcOEt, (4/1 to 2/1). $[\alpha]_{\text{D}}^{20}$ -27.1 (*c* 0.78, in CHCl_3). ^1H NMR (CDCl_3): δ 4.45-4.38 (m, 1H), 3.83 (d, *J* = 6.4 Hz, 1H), 2.74 (dd, *J* = 16.0, 7.8 Hz, 1H), 2.61 (dd, *J* = 15.9, 5.6 Hz, 1H), 1.44 (s, 9H), 1.19 (s, 9H), 0.14 (s, 9H). ^{13}C NMR (CDCl_3): δ 169.6, 103.8, 90.2, 81.7, 56.4, 45.4, 43.4, 28.3, 22.7, 0.0.

Sulfonamide deprotection:

General procedure E. The corresponding sulfonamide (0.0815 mmol) was treated with HCl in MeOH (0.163 mmol, 1.15 M). The mixture stirred at room temperature for 90 min. Then, the reaction mixture was concentrated *in vacuo*, and H_2O (5 mL) and HCl (1 M) were added (to acid pH). The aqueous layer was washed with AcOEt (2 x 10 mL), being the organic layers discarded. The aqueous layer neutralized and extracted with AcOEt (3 x 10 mL). The organic phases dried over MgSO_4 , filtered and the solvent was evaporated under reduced pressure.

tert-Butyl (*S*)-3-amino-5-phenylpent-4-ynoate (**4a**)

Following the general procedure E, sulfonamide **3a** (0.086 mmol) after 16 h, gave **4a** (21 mg, 0.086 mmol, 100%). $[\alpha]_{\text{D}}^{20}$ -8.3 (*c* 0.41, in CHCl_3). ^1H NMR (CDCl_3): δ 7.40-7.37 (m, 2H), 7.29-7.26 (m, 3H), 4.22-4.18 (m, 1H), 2.68 (dd, *J* = 15.6, 5.6 Hz, 1H), 2.61 (dd, *J* = 15.6, 7.5 Hz, 1H), 1.82 (s, 1H), 1.47 (s, 9H). ^{13}C NMR (CDCl_3): δ 170.2, 131.6, 128.2, 128.1, 123.0, 82.7, 81.0 (2C), 44.0, 41.0, 28.1. IR (NaCl): 2977, 2926, 2854, 1729, 1600, 1368, 1259, 1149 cm^{-1} . MS (FAB+): *m/z* (%): 246 ($\text{M}+1$)⁺ (30), 190 (39), 173 (45), 131 (29), 73 (30), 57 (100). HRMS: *m/z* calcd for $\text{C}_{15}\text{H}_{20}\text{NO}_2$ [$\text{M}+\text{H}$]⁺: 246.1494; found: 246.1495.

tert-Butyl (*S*)-3-aminodec-4-ynoate (**4f**)

Following the general procedure E, sulfonamide **3f** (0.086 mmol) after 16 h, gave **4f** (20 mg, 0.081 mmol, 94%). $[\alpha]_{\text{D}}^{20}$ -9.1 (*c* 0.43, in CHCl_3). ^1H NMR (CDCl_3): δ 3.95 (s, 1H), 2.59-2.43 (m, 2H), 2.17-2.12 (m, 2H), 1.83 (s, 2H), 1.45 (s, 9H), 1.38-1.25 (m, 6H), 0.91-0.86 (m, 3H). ^{13}C NMR (CDCl_3): δ 170.5, 83.2, 80.8, 44.4, 40.6, 31.0, 29.7, 28.4, 28.1, 22.2, 18.6, 14.0. IR (NaCl): 2959, 2930, 2858, 1731, 1458, 1368, 1256, 1150 cm^{-1} . MS (ESI+): *m/z* (%): 460 (6), 240 ($\text{M}+1$)⁺ (11), 184 (100), 167 (10). HRMS: *m/z* calcd for $\text{C}_{14}\text{H}_{26}\text{NO}_2$ [$\text{M}+\text{H}$]⁺: 240.1958; found: 240.1969.

β -Amino acid synthesis. Ester hydrolysis

General procedure F. The sulfonamide (0.0815 mmol) was treated with HCl/ H_2O (6N). The mixture was stirred at 40°C. After 15 h the solvent was evaporated *in vacuo*.

(*S*)-3-Amino-5-phenylpent-4-ynoic acid hydrochloride (**5a**)

Following the general procedure F, sulfonamide **3a** (0.086 mmol) after 1.5 h, gave **5a** (15 mg, 0.08 mmol, 91%). $[\alpha]_{\text{D}}^{20}$ -3.7 (*c* 0.66, in MeOH). ^1H NMR (CD_3OD): δ 6.15-6.13 (m, 2H), 6.08-6.03 (m, 3H), 3.36-3.32 (m, 1H), 1.97 (s, 2H), 1.72-1.63 (m, 2H). ^{13}C NMR (CD_3OD): δ 170.8, 131.4, 129.1, 128.2, 120.9, 86.7, 82.0, 39.8, 37.0. IR (NaCl): 3590, 3421, 2918, 2850, 2243, 1717, 1595, 1490, 1400, 1187 cm^{-1} . MS (FAB+): *m/z* (%): 212 ($\text{M}^+ + \text{Na}$) (7), 190 ($\text{M}+1$)⁺ (16), 173 (27), 131 (100). HRMS: *m/z* calcd for $\text{C}_{11}\text{H}_{12}\text{NO}_2$ [$\text{M}+\text{H}$]⁺: 190.0862; found: 190.0871.

(*S*)-3-Aminodec-4-ynoic acid hydrochloride (**5f**)

Following the general procedure F, sulfonamide **3f** (0.086 mmol) after 1.5 h, gave **5f** (15 mg, 0.08 mmol, 93%). $[\alpha]_{\text{D}}^{20}$ -10.8 (*c* 0.83, in MeOH). ^1H NMR (CD_3OD): δ 2.89-2.83 (m, 2H), 2.32-2.25 (m, 2H), 1.59-1.51 (s, 2H), 1.46-1.34 (m, 6H), 0.94 (t, *J* = 6.8 Hz, 3H). ^{13}C NMR (CD_3OD): δ 131.4, 89.7, 75.1, 41.1, 32.0, 30.0, 29.0, 23.2, 19.1, 14.2. MS (FAB+): *m/z* (%): 206 ($\text{M} + \text{Na}$)⁺ (33), 201 ($\text{M} + \text{NH}_4$)⁺ (38), 184 ($\text{M}+1$)⁺ (100), 167 (7), 157 (8), 121 (5). HRMS: *m/z* calcd for $\text{C}_{10}\text{H}_{18}\text{NO}_2$ [$\text{M}+\text{H}$]⁺: 184.1332; found: 184.1362.

Supporting Information Available. The Supporting Information is available free of charge on the ACS Publication website at DOI: 10.1021/acs.joc.7b01211. Copies of ^1H and ^{13}C spectra for all new compounds and X-ray data for compound **3g** are included. This material is free of charge via the Internet at <http://pubs.acs.org>.

Corresponding Authors

*E-MAIL: (JAFS) j.fernandez@uam.es; (MCM) carmen.maestro@uam.es

ACKNOWLEDGMENTS

We are grateful to the Spanish Government (CTQ2015-64561-R) and the European Research Council (ERC-CG-UNBICAT, contract number: 647550). J. A. F.-S. thanks the Spanish Government for a Juan de la Cierva Contract.

REFERENCES

- (1) (a) Farina, V.; Reeves, J. T.; Senanayake C. H.; Song, J. J. Asymmetric Synthesis of Active Pharmaceutical Ingredients. *Chem. Rev.* **2006**, *106*, 2734-2793. (b) Breuer, M.; Ditrich, K.; Habicher, T.; Hauer, B.; Keßeler, M.; Stürmer, R.; Zelinski, T. Industrial Methods for the Production of Optically Active Intermediates. *Angew. Chem. Int. Ed.* **2004**, *43*, 788-824.
- (2) (a) Enantioselective Synthesis of β -Amino Acids; Juaristi, E. Ed. Wiley-VCH: New York, 2005. (b) Shinagawa, S.; Kanamaru, T.; Harada, S.; Asai, M.; Okazaki, H. Chemistry of emeramine and its analogs and their inhibitory activity in long-chain fatty acid oxidation. *J. Med. Chem.* **1987**, *30*, 1458-1463. (c) Kubota, D.; Ishikawa, M.;

1 Yamamoto, M.; Murakami, S.; Hachisu, M.; Katano K.;
2 Ajito, K. Tricyclic pharmacophore-based molecules as
3 novel integrin $\alpha_v\beta_3$ antagonists. Part 1: Design and synthe-
4 sis of a lead compound exhibiting $\alpha_v\beta_3/\alpha_{IIb}\beta_3$ dual antago-
5 nistic activity. *Bioorg. Med. Chem. Lett.* **2006**, *14*, 2089-
6 2108. (d) Namikoshi, M.; Rinehart, K. L.; Dahlem, A. M.;
7 Beasley V. R.; Carmichael, W. W. Total synthesis of Adda,
8 the unique C₂₀ amino acid of cyanobacterial hepatotoxins
9 *Tetrahedron Lett.* **1989**, *30*, 4349-4352. (e) Nussbaum, F.
10 von; Spitteller, P.; R uth, M.; Steglich, W.; Wanner, G.; Gam-
11 blin, B.; Stievano L.; Wagner, F. E. An Iron(III)-Catechol
12 Complex as a Mushroom Pigment. *Angew. Chem. Int. Ed.*,
13 **1998**, *37*, 3292-3295. (f) Spitteller, P.; R uth, M.; Nussbaum F.
14 von; Steglich, W. Detection of a 2,3-Aminomutase in the
15 Mushroom *Cortinarius violaceus*. *Angew. Chem. Int. Ed.*,
16 **2000**, *39*, 2754-2756. (g) Crews, P.; Manes, L. V.; Boehler,
17 M. Jaspilakinolide, a cyclodepsipeptide from the marine
18 sponge. *Tetrahedron Lett.*, **1986**, *27*, 2797-2800.

19 (3) (a) Brandi, A.; Cicchi S.; Cordero, F. M. Novel Syn-
20 theses of Azetidines and Azetidiones. *Chem. Rev.* **2008**,
21 *108*, 3988-4035. (b) Pitts C. R.; Lectka, T. Chemical Synthe-
22 sis of β -Lactams: Asymmetric Catalysis and Other Recent
23 Advances. *Chem. Rev.* **2014**, *114*, 7930-7953.

24 (4) Cheng, R. P.; Gellman S. H.; DeGrado, W. F. β -
25 Peptides: From Structure to Function. *Chem. Rev.* **2001**,
26 *101*, 3219-3232.

27 (5) For reviews, see: (a) Weiner, B.; Szymanski, W.;
28 Janssen, D. B.; Minnaard A. J.; Feringa, B. L. Recent ad-
29 vances in the catalytic asymmetric synthesis of β -amino
30 acids. *Chem. Soc. Rev.* **2010**, *39*, 1656-1691 and references
31 cited therein. (b) Ashfaq, M.; Tabassum, R.; Ahmad, M.
32 M.; Hassan, N. A.; Oku H., Rivera, G. Enantioselective
33 Synthesis of β -amino acids: A Review. *Med. Chem.* **2015**, *5*,
34 295-309. For selected recent examples, see: (c) Li, X.; You,
35 C.; Li, S.; Lv H.; Zhang, X. Nickel-Catalyzed Enantioselective
36 Hydrogenation of β -(Acylamino)acrylates: Synthesis
37 of Chiral β -Amino Acid Derivatives. *Org. Lett.* **2017**, *19*,
38 5130-5133. (d) Zhou F.; Yamamoto, H. A Disulfonimide
39 Catalyst for Highly Enantioselective Mukaiyama-Mannich
40 Reaction *Org. Lett.* **2016**, *18*, 4124-4127. (e) Campello, H.
41 R.; Parker, J.; Perry, M.; Ryberg P.; Gallagher, T. Asymmet-
42 ric Reduction of Lactam-Based β -Aminoacrylates. Syn-
43 thesis of Heterocyclic β -Amino Acids. *Org. Lett.* **2016**, *18*,
44 4974-4977; (f) Cant -Reyes, M.; Alvarado-Beltr n, I.;
45 Ballinas-Indil , R.;  lvarez-Toledano C.; Hern ndez-
46 Rodr guez, M. Stereodivergent Mannich reaction of
47 bis(trimethylsilyl)ketene acetals with *N*-tert-
48 butanesulfinyl imines by Lewis acid or Lewis base activa-
49 tion, a one-pot protocol to obtain chiral β -amino acids
50 *Org. Biomol. Chem.*, **2017**, *15*, 7705-7709. (g) Wang, Y.; Mo,
51 M.; Zhu, K.; Zheng, C.; Zhang, H. Asymmetric synthesis of
52 syn-propargylamines and unsaturated β -amino acids under
53 Br nsted base catalysis. *Nat. Commun.*, **2015**,
54 *10.1038/ncomms9544*.

55 (6) For general review of *N*-sulfinyl imines, see: (a)
56 Robak, M. A. T.; Herbage M. A.; Ellman, J. A. Synthesis and
57 Applications of *tert*-Butanesulfinamide. *Chem. Rev.* **2010**,

58 *110*, 3600-3740. For Mannich reaction to *N*-sulfinyl imines,
59 see: (b) Tang T. P.; Ellman, J. A. Asymmetric Synthesis of
60 β -Amino Acid Derivatives Incorporating a Broad Range of
Substitution Patterns by Enolate Additions to *tert*-
Butanesulfinyl Imines. *J. Org. Chem.* **2002**, *67*, 7819-7832.
For aza-Reformatsky reaction to *N*-sulfinyl imines, see: (c)
Girgis, M. J.; Liang, J. K.; Du, Z.; Slade J.; Prasad, K. A Scal-
able Zinc Activation Procedure Using DIBAL-H in a
Reformatsky Reaction. *Org. Process Res. Dev.* **2009**, *13*,
1094-1099. (d) Grellepois, F. Enantiopure Trifluoromethyl-
ated β , β -Amino Acids: Synthesis by Asymmetric Refor-
matsky Reaction with Stable Analogues of Trifluoromethyl
N-*tert*-Butanesulfinylketoinimes and Incorporation into
 α/β -Peptides. *J. Org. Chem.* **2013**, *78*, 1127-1137. (e) Brinner,
K.; Doughan B.; Poon, D. J. Scalable Synthesis of β -Amino
Esters via Reformatsky Reaction with *N*-*tert*-
Butanesulfinyl Imines. *Synlett*, **2009**, *6*, 991-993.

(7) For Reformatsky reaction reviews, see: (a) Choppin,
S.; Ferreiro-Medeiros, L.; Barbarottoa M.; Colobert, F.
Recent advances in the diastereoselective Reformatsky-
type reaction. *Chem. Soc. Rev.* **2013**, *42*, 937-949. (b) Pellis-
sier, H. Recent developments in the asymmetric Refor-
matsky-type reaction. *Beilstein J. Org. Chem.* **2018**, *14*, 325-
344.

(8) (a) Anders, R.; Kleiman, J.; Nicholson, N.; Wazowicz,
B.; Burns, D. Xemilofiban/Orbofiban: Insight into Drug
Development *Cardiovascular Drug Rev.* **2001**, *19*, 116-132. (b)
Zablocki, J. A.; Rico, J. G.; Garland, R. B.; Rogers, T. E.;
Williams, K.; Schretzman, L. A.; Rae, S. A.; Bow, P. R.;
Tjoeng, F. S.; Lindmark, R. J.; Toth, M. V.; Zupec, M. E.;
McMackins, D. E.; Adams, S. P.; Miyano, M.; Markos, C. S.;
Milton, M. N.; Paulson, S.; Herin, M.; Jacqmin, P.; Nichol-
son, N. S.; Panzer-Knodle, S. G.; Haas, N. F.; Page, J. D.;
Szalony, J. A.; Taite, B. B.; Salyers, A. K.; King, L. W.; Cam-
pion, J. G.; L. P. Feigen. Potent in Vitro and in Vivo Inhibi-
tors of Platelet Aggregation Based Upon the Arg-Gly-Asp
Sequence of Fibrinogen. (Aminobenzamidino)succinyl
(ABAS) Series of Orally Active Fibrinogen Receptor Antag-
onists. *J. Med. Chem.* **1995**, *38*, 2378-2394. (c) Hoekstra, W.
J.; Maryanoff, B. E.; Damiano, B. P.; Andrade-Gordon, P.;
Cohen, J. H.; Costanzo, M. J.; Haertlein, B. J.; Hecker, L. R.;
Hulshizer, B. L.; Kauffman, J. A.; Keane, P.; McComsey, D.
F.; Mitchell, J. A.; Scott, L.; Shah, R. D.; Yabut, S. C.
†Potent, Orally Active GPIIb/IIIa Antagonists Containing a
Nipepic Acid Subunit. Structure-Activity Studies Lead-
ing to the Discovery of RWJ-53308. *J. Med. Chem.* **1999**, *42*,
5254-5265. (d) Scarborough R. M.; Gretler, D. D. Platelet
Glycoprotein IIb-IIIa Antagonists as Prototypical Integrin
Blockers: Novel Parenteral and Potential Oral Antithrom-
botic Agents. *J. Med. Chem.*, **2000**, *43*, 3453-3473, and refer-
ences cited therein.

(9) (a) Lauder, K.; Toscani, A.; Scalacci, N.; Castagnolo,
D. Synthesis and Reactivity of Propargylamines in Organ-
ic Chemistry. *Chem. Rev.* **2017**, *117*, 14091-14200. (b) For a
recent enantioselective synthesis of propargyl amides see:
Bai, X.-Y.; Zhang, W.-W.; Li Q.; Li, B.-J. Highly Enantioselective
Synthesis of Propargyl Amides through Rh-

Catalyzed Asymmetric Hydroalkynylation of Enamides: Scope, Mechanism, and Origin of Selectivity. *J. Am. Chem. Soc.* **2018**, *140*, 506-514, and references cited therein.

(10) For the synthesis of γ,δ -alkynyl- β -amino acid via enzymatic kinetic resolution, see: (a) Landis, B. H.; Mullins, P. B.; Mullins, K. E.; Wang, P. T. Kinetic Resolution of β -Amino Esters by Acylation Using Immobilized Penicillin Amidohydrolase. *Org. Proc. Res. Dev.* **2002**, *6*, 539-546. (b) Yamanaka, T.; Ohkubo, M.; Takahashi, F.; Kato, M. An efficient synthesis of the orally-active GpIIb/IIIa antagonist FR184764. *Tetrahedron Letters*, **2004**, *45*, 2843-2845.

(11) In situ generation of alkynyl imines: (a) Kano, T.; Yurino, T.; Maruoka, K. Organocatalytic Asymmetric Synthesis of Propargylamines with Two Adjacent Stereocenters: Mannich-Type Reactions of *In Situ* Generated C-Alkynyl Imines with β -Keto Esters. *Angew. Chem. Int. Ed.* **2013**, *52*, 11509-11512. (b) Yurino, T.; Aota, Y.; Asakawa, D.; Kano, T.; Maruoka, K. N-Boc-aminals as easily accessible precursors for less accessible N-Boc-imines: facile synthesis of optically active propargylamine derivatives using Mannich-type reactions. *Tetrahedron* **2016**, *72*, 3687-3700. (c) Hayashi, Y.; Yamazaki, T.; Kawauchi, G.; Sato, I. Proline Salt as a Catalyst in the syn-Selective, Asymmetric Mannich Reaction of Alkynyl Imine. *Org. Lett.* **2018**, *20*, 2391-2394.

(12) (a) Josephsohn, N. S.; Carswell, E. L.; Snapper, M. L.; Hoveyda, A. H. Practical and Highly Enantioselective Synthesis of β -Alkynyl- β -amino Esters through Ag-Catalyzed Asymmetric Mannich Reactions of Silylketene Acetals and Alkynyl Imines. *Org. Lett.* **2005**, *7*, 2711-2713. (b) Wang, J.; Shao, Z.; Yu, K. D. W. Y.; Chan, A. S. C. Copper(I)-Catalyzed Asymmetric Addition of Terminal Alkynes to β -Imino Esters: An Efficient and Direct Method in the Synthesis of Chiral β_3 -Alkynyl $\beta_{2,2}$ -Dimethyl Amino Acid Derivatives. *Adv. Synth. Catal.* **2009**, *351*, 1250-1254. (c) Awasthi, A. K.; Boys, M. L.; Cain-Janicki, K. J.; Colson, P.-J.; Doubleday, W. W.; Duran, J. E.; Farid, P. N. Practical Enantioselective Synthesis of β -Substituted- β -amino Esters. *J. Org. Chem.* **2005**, *70*, 5387-5397. (d) Saito, S.; Hatanaka, K.; Yamamoto, H. Asymmetric Mannich-Type Reactions of Aldimines with a Chiral Acetate. *Org. Lett.*, **2000**, *2*, 1891-1894. (e) Lapuerta, I.; Vera, S.; Oiarbide, M.; Palomo, C. Catalytic Enantioselective Aza-Reformatsky Reaction with Cyclic Imines. *Chem. Eur. J.* **2016**, *22*, 7229-7237.

(13) (a) Kano, T.; Aota, Y.; Maruoka, K. Asymmetric Synthesis of Less Accessible α -Tertiary Amines from Alkynyl Z-Ketimines. *Angew. Chem. Int. Ed.* **2017**, *56*, 16293-16296. For other examples of the addition of lithium acetylides to N-*t*-butanesulfinyl ketimines, see: (b) Xu, C.; Chowdhury, S.; Ellman, J. A. Asymmetric synthesis of amines using *tert*-butanesulfinamide. *Nature Protocols*, **2013**, *8*, 2271-2280. (c) Patterson, A. W.; Ellman, J. A. Asymmetric Synthesis of α,α -Dibranched Propargylamines by Acetylide Additions to N-*tert*-Butanesulfinyl Ketimines. *J. Org. Chem.* **2006**, *71*, 7110-7112. For the synthesis of α -tertiary phenyl difluoromethyl propargylamines see: (d) Liu, J.; Hu, J. Highly Diastereoselective Synthesis of α -

Difluoromethyl Amines from N-*tert*-Butylsulfinyl Ketimines and Difluoromethyl Phenyl Sulfone. *Chem. Eur. J.* **2010**, *16*, 11443-11454.

(14) (a) Krautwald, S.; Carreira, E. M. Stereodivergence in Asymmetric Catalysis. *J. Am. Chem. Soc.* **2017**, *139*, 5627-5639. (b) Sun, X.-W.; Xu, M.-H.; Lin, G.-Q. Room-Temperature Highly Diastereoselective Zn-Mediated Alkylation of Chiral N-*tert*-Butanesulfinyl Imines: Remarkable Reaction Condition Controlled Stereoselectivity Reversal. *Org. Lett.* **2006**, *8*, 4979-4982.

(15) When the reaction was carried out at lower temperature (-40 °C or -10 °C), lower conversion to the desired products (specially with imines bearing functional groups such as esters (**1c**), which demonstrated lower tolerance at higher temperatures) were obtained.

(16) See the Supporting Information for X-ray structure. CCDC 1850070 (**3g**) contain the supplementary crystallographic data for this paper. This data can be obtained free of charge from The Cambridge Crystallographic Data Centre.

(17) (a) Cogan, D. A.; Liu, G.; Ellman, J. Asymmetric Synthesis of Chiral Amines by Highly Diastereoselective 1,2-Additions of Organometallic Reagents to N-*tert*-Butanesulfinyl Imines. *Tetrahedron*, **1999**, *55*, 8883-8904. (b) Staas, D. D.; Savage, K. L.; Homnick, C. F.; Tsou, N. N.; Ball, R. G. Asymmetric Synthesis of α,α -Difluoro- β -amino Acid Derivatives from Enantiomerically Pure N-*tert*-Butylsulfinimines. *J. Org. Chem.* **2002**, *67*, 8276-8279.

(18) Plobeck, N.; Powell, D. Asymmetric synthesis of diarylmethylamines by diastereoselective addition of organometallic reagents to chiral N-*tert*-butanesulfinimines: switchover of diastereofacial selectivity. *Tetrahedron: Asymmetry*, **2002**, *13*, 303-310. Me₃Al could also be involved in differentiating the two Me₃Al imine isomers reaction rates, which are in rapid equilibrium, see *ref.* 16a.

(19) (a) Davis, F. A.; Friedman, A. J.; Kluger, E. W. Chemistry of the Sulfur-Nitrogen Bond. VIII. N-Alkylidensulfinamides. *J. Am. Chem. Soc.* **1974**, *96*, 5000-5001. (b) Davis, F. A.; Kluger, E. W. Chemistry of the Sulfur-Nitrogen Bond. X. *J. Am. Chem. Soc.* **1976**, *98*, 302-303.

(20) Ferreira, F.; Audouin, M.; Chemla, F. Influence of HMPA on the Stereochemical Outcome of the Addition of a Racemic Allenylzinc onto Enantiopure N-*tert*-Butanesulfinimines: Stereoselective Access to Enantiopure *cis*-Ethynylaziridines. *Chem. Eur. J.* **2005**, *11*, 5269-5278.

(21) To a solution of zinc (0.0344 mmol) in THF anhydrous (0.4 mL) under argon atmosphere, *tert*-butyl 2-bromoacetate (0.344 mmol) was added. The mixture was stirred for 30 min at reflux (it gets a greenish color). After the complete dissolution of the metal, the reaction was cooled until the corresponding temperature.